Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Researchers identify ways to inhibit function of key protein linked to stem cell-like behavior in CML

Researchers identify ways to inhibit function of key protein linked to stem cell-like behavior in CML

Three easy steps for cancer survivorship

Three easy steps for cancer survivorship

Survival rates increased among patients who received blood stem cell transplants: Study

Survival rates increased among patients who received blood stem cell transplants: Study

DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

GATA-3 protein plays an important role in mammalian immune response

GATA-3 protein plays an important role in mammalian immune response

Liposomal anthracycline-based chemotherapy effective for children with leukemia: Study

Liposomal anthracycline-based chemotherapy effective for children with leukemia: Study

Cancer experts to discuss latest developments and implications of cell therapies in oncology

Cancer experts to discuss latest developments and implications of cell therapies in oncology

Caltech biologists show that microRNA-146a protects stem cells during inflammation

Caltech biologists show that microRNA-146a protects stem cells during inflammation

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

New computational method may help track tumor progression, risk of relapse

New computational method may help track tumor progression, risk of relapse

BioLineRx signs ATM sales agency agreement with Stifel

BioLineRx signs ATM sales agency agreement with Stifel

Viewpoints: When a doctor should keep quiet; 2 views of hospital pricing; Stem cell 'snake oil'

Viewpoints: When a doctor should keep quiet; 2 views of hospital pricing; Stem cell 'snake oil'

People diagnosed with cancer are more likely to declare bankruptcy

People diagnosed with cancer are more likely to declare bankruptcy

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

Secure cloud-based computing system to access, analyze human genomic cancer information

Secure cloud-based computing system to access, analyze human genomic cancer information

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

Annual Century for the Cure bike ride supports research on hematologic malignancies

Annual Century for the Cure bike ride supports research on hematologic malignancies

NCCC doctors find effective drug combination to treat chronic lymphocytic leukemia

NCCC doctors find effective drug combination to treat chronic lymphocytic leukemia

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.